<p>在今天发布的一份报告中，JonesTrading 的 Debanjana Chatterjee 维持了对 EyePoint Pharmaceuticals 的买入评级，目标价为 43.00 美元。</p>
<h3>享受 TipRanks Premium 50% 的折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Debanjana Chatterjee 的评级基于 EyePoint Pharmaceuticals 在湿性年龄相关性黄斑变性（wet AMD）领域的强大监管和临床定位，特别是其候选药物 Duravyu。该公司正在进行两项大型、严格控制的第三阶段临床试验 LUGANO 和 LUCIA，旨在满足熟悉的监管标准并提高成功的可能性。这一战略方法与 FDA 的指导方针相一致，可能允许基于单个第三阶段试验获得批准，从而加快监管流程。</p>
<p>此外，湿性 AMD 市场的未满足需求，如关键意见领袖所强调的，突显了 Duravyu 的潜在影响。目前的治疗方法如 Vabysmo 和 Eylea HD 耐久性有限，经济限制进一步限制了其可及性。EyePoint 的候选药物旨在填补这些空白，提供更持久的解决方案，可能显著改善患者的治疗效果并减轻经济负担，从而证明了买入评级的合理性。</p>
<p>在 12 月 9 日发布的另一份报告中，瑞穗证券也重申了对该股票的买入评级，目标价为 33.00 美元。</p>

EYPT

<p>JonesTrading 的 Debanjana Chatterjee 对 EyePoint Pharmaceuticals 维持买入评级，目标价为 43 美元，理由是其湿性年龄相关性黄斑变性候选药物 Duravyu 的临床定位强劲。该公司正在进行两项第三阶段临床试验，LUGANO 和 LUCIA，符合 FDA 的指导方针，以期获得加速批准。Duravyu 旨在满足湿性年龄相关性黄斑变性市场的未满足需求，提供相比当前治疗方案更持久的解决方案。瑞穗证券也重申了买入评级，目标价为 33 美元</p>

<p>In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals, with a price target of $43.00.</p>
<div class="lb-trans"><p>在今天发布的一份报告中，JonesTrading 的 Debanjana Chatterjee 维持了对 EyePoint Pharmaceuticals 的买入评级，目标价为 43.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 的折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Debanjana Chatterjee’s rating is based on EyePoint Pharmaceuticals’ strong regulatory and clinical positioning, particularly with its candidate Duravyu in the wet AMD landscape. The company is conducting two large, well-controlled Phase 3 trials, LUGANO and LUCIA, which are designed to meet familiar regulatory standards and enhance the likelihood of success. This strategic approach aligns with the FDA’s guidance, potentially allowing for approval based on a single Phase 3 trial, which could expedite the regulatory process.</p>
<div class="lb-trans"><p>Debanjana Chatterjee 的评级基于 EyePoint Pharmaceuticals 在湿性年龄相关性黄斑变性（wet AMD）领域的强大监管和临床定位，特别是其候选药物 Duravyu。该公司正在进行两项大型、严格控制的第三阶段临床试验 LUGANO 和 LUCIA，旨在满足熟悉的监管标准并提高成功的可能性。这一战略方法与 FDA 的指导方针相一致，可能允许基于单个第三阶段试验获得批准，从而加快监管流程。</p>
</div><p>Additionally, the unmet need in the wet AMD market, as highlighted by a key opinion leader, underscores the potential impact of Duravyu. Current treatments like Vabysmo and Eylea HD have limited durability, and economic constraints further limit their accessibility. EyePoint’s candidate aims to address these gaps, offering a more durable solution that could significantly improve patient outcomes and reduce economic strain, thereby justifying the Buy rating.</p>
<div class="lb-trans"><p>此外，湿性 AMD 市场的未满足需求，如关键意见领袖所强调的，突显了 Duravyu 的潜在影响。目前的治疗方法如 Vabysmo 和 Eylea HD 耐久性有限，经济限制进一步限制了其可及性。EyePoint 的候选药物旨在填补这些空白，提供更持久的解决方案，可能显著改善患者的治疗效果并减轻经济负担，从而证明了买入评级的合理性。</p>
</div><p>In another report released on December 9, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.</p>
<div class="lb-trans"><p>在 12 月 9 日发布的另一份报告中，瑞穗证券也重申了对该股票的买入评级，目标价为 33.00 美元。</p>
</div>

Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD

- Debanjana Chatterjee 维持 EyePoint Pharmaceuticals 的买入评级，目标价为 $43.00。  
- 公司在湿性 AMD 领域的 Duravyu 候选药物进行两项大型 III 期试验，符合监管标准。  
- 该药物有望解决现有治疗的耐久性不足问题，改善患者结果。  

买入建议：EyePoint 制药公司在湿性年龄相关性黄斑变性中 Duravyu 的强大临床定位和市场潜力